Nintedanib, an already approved treatment for IPF and other progressive fibrosing interstitial lung diseases, has been shown to suppress lung fibroblast proliferation, motility, and myofibroblast differentiation.36, 37, 38, 39, 40, 41, 42It also reduces TGF-β1-induced collagen production but has minimal effect on HSP47 protein levels, despite lowering its mRNA throughSERPINH1suppression. Here, SERPINH1 is linked to idiopathic pulmonary fibrosis.